$REEMF
RARE ELEMENT RESOURCES LTD

2023 Q2 Form 10-Q Financial Statement

#000141980623000010 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $613.0K $742.0K
YoY Change -63.45% -49.52%
% of Gross Profit
Research & Development $2.165M $1.510M
YoY Change 149.71% 139.68%
% of Gross Profit
Depreciation & Amortization $26.00K $25.00K
YoY Change 2400.0%
% of Gross Profit
Operating Expenses $2.804M $2.277M
YoY Change 9.19% 7.1%
Operating Profit
YoY Change
Interest Expense $8.000K $8.000K
YoY Change -61.9% 700.0%
% of Operating Profit
Other Income/Expense, Net $60.00K $55.00K
YoY Change -203.45% -178.57%
Pretax Income -$2.744M -$2.222M
YoY Change 4.49% 1.18%
Income Tax
% Of Pretax Income
Net Earnings -$2.744M -$2.222M
YoY Change 4.49% 1.18%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 212.6M 212.5M
Diluted Shares Outstanding 212.6M 212.5M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.45M $13.99M
YoY Change -45.4% -34.82%
Cash & Equivalents $11.45M $13.99M
Short-Term Investments
Other Short-Term Assets $1.774M $2.026M
YoY Change 145.71% 53.02%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.51M $16.10M
YoY Change -38.03% -30.4%
LONG-TERM ASSETS
Property, Plant & Equipment $31.00K $15.00K
YoY Change 106.67% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $854.0K $863.0K
YoY Change -8.96% -10.29%
TOTAL ASSETS
Total Short-Term Assets $13.51M $16.10M
Total Long-Term Assets $854.0K $863.0K
Total Assets $14.36M $16.97M
YoY Change -36.83% -29.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $253.0K $329.0K
YoY Change -44.27% 18.77%
Accrued Expenses $124.0K $124.0K
YoY Change 0.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $377.0K $453.0K
YoY Change -34.78% 12.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.676M $1.629M
YoY Change 11.14% 11.73%
Total Long-Term Liabilities $1.676M $1.629M
YoY Change 11.14% 11.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $377.0K $453.0K
Total Long-Term Liabilities $1.676M $1.629M
Total Liabilities $2.053M $2.082M
YoY Change -1.58% 12.0%
SHAREHOLDERS EQUITY
Retained Earnings -$153.6M -$150.9M
YoY Change 6.64% 6.68%
Common Stock $136.9M $136.9M
YoY Change 0.01% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.31M $14.89M
YoY Change
Total Liabilities & Shareholders Equity $14.36M $16.97M
YoY Change -36.83% -29.59%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$2.744M -$2.222M
YoY Change 4.49% 1.18%
Depreciation, Depletion And Amortization $26.00K $25.00K
YoY Change 2400.0%
Cash From Operating Activities -$2.529M -$1.543M
YoY Change 418.24% -55.67%
INVESTING ACTIVITIES
Capital Expenditures $16.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $12.00K
YoY Change
Cash From Investing Activities -$16.00K $12.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.000K
YoY Change
NET CHANGE
Cash From Operating Activities -2.529M -1.543M
Cash From Investing Activities -16.00K 12.00K
Cash From Financing Activities 7.000K
Net Change In Cash -2.538M -1.531M
YoY Change 420.08% -56.02%
FREE CASH FLOW
Cash From Operating Activities -$2.529M -$1.543M
Capital Expenditures $16.00K
Free Cash Flow -$2.545M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2022Q4 reemf Investment In Land
InvestmentInLand
600000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
172000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
995000
CY2022Q1 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
25000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
212466889
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
212515951
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Rare Element Resources Ltd
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001419806
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2023Q1 reemf Percentage Of Total Estimated Cost For Project Covered By Funding
PercentageOfTotalEstimatedCostForProjectCoveredByFunding
0.50
CY2021Q4 reemf Percentage Of Total Estimated Cost For Project Covered By Funding
PercentageOfTotalEstimatedCostForProjectCoveredByFunding
0.5
CY2021Q4 reemf Percentage Of Total Estimated Cost For Project Covered By Funding
PercentageOfTotalEstimatedCostForProjectCoveredByFunding
0.5
CY2021Q4 reemf Percentage Of Total Estimated Cost For Project Covered By Funding
PercentageOfTotalEstimatedCostForProjectCoveredByFunding
0.5
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-34852
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
P.O. Box 271049
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Littleton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80127
CY2023Q1 dei City Area Code
CityAreaCode
720
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
278-2460
CY2023Q1 dei Security12b Title
Security12bTitle
None
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
212613451
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13992000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15523000
CY2023Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
86000
CY2022Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
174000
CY2023Q1 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
1866000
CY2022Q4 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
2142000
CY2023Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
160000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
140000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
16104000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
17979000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
248000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
273000
CY2023Q1 reemf Investment In Land
InvestmentInLand
600000
CY2023Q1 us-gaap Assets
Assets
16967000
CY2022Q4 us-gaap Assets
Assets
18867000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
329000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
227000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
453000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
351000
CY2023Q1 us-gaap Mine Reclamation And Closing Liability Noncurrent
MineReclamationAndClosingLiabilityNoncurrent
132000
CY2022Q4 us-gaap Mine Reclamation And Closing Liability Noncurrent
MineReclamationAndClosingLiabilityNoncurrent
132000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
168000
CY2023Q1 us-gaap Derivative Liability Securities Sold Under Agreements To Resell Securities Loaned Gross
DerivativeLiabilitySecuritiesSoldUnderAgreementsToResellSecuritiesLoanedGross
1351000
CY2022Q4 us-gaap Derivative Liability Securities Sold Under Agreements To Resell Securities Loaned Gross
DerivativeLiabilitySecuritiesSoldUnderAgreementsToResellSecuritiesLoanedGross
1281000
CY2023Q1 us-gaap Liabilities
Liabilities
2082000
CY2022Q4 us-gaap Liabilities
Liabilities
1932000
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
212515951
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
212515951
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
136906000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
136906000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
28845000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
28673000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150866000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148644000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
14885000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16935000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16967000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18867000
CY2023Q1 us-gaap Exploration Expense
ExplorationExpense
1510000
CY2022Q1 us-gaap Exploration Expense
ExplorationExpense
630000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
742000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1470000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
25000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
26000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2277000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2126000
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
122000
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
1000
CY2023Q1 us-gaap Accretion Expense
AccretionExpense
71000
CY2022Q1 us-gaap Accretion Expense
AccretionExpense
71000
CY2023Q1 us-gaap Interest Expense
InterestExpense
8000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
12000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
55000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-70000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2222000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2196000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212466889
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2222000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2196000
CY2022Q1 us-gaap Depreciation
Depreciation
1000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212515951
CY2023Q1 us-gaap Accretion Expense
AccretionExpense
71000
CY2022Q1 us-gaap Accretion Expense
AccretionExpense
71000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
25000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
25000
CY2023Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
-22000
CY2022Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
-20000
CY2023Q1 reemf Adjustments To Reconcile Net Income Loss To Cash Used In Provided By Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashUsedInProvidedByOperatingActivities
-1976000
CY2022Q1 reemf Adjustments To Reconcile Net Income Loss To Cash Used In Provided By Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashUsedInProvidedByOperatingActivities
-1149000
CY2023Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-88000
CY2022Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
241000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-242000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1249000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
103000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-842000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1543000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3481000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1531000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3481000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15523000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24947000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13992000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21466000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23441000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
995000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2196000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
22240000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16935000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
172000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2222000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
14885000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> NATURE OF OPERATIONS</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rare Element Resources Ltd. (“we,” “us,” “Rare Element” or the “Company”) was incorporated under the laws of the Province of British Columbia, Canada, on June 3, 1999.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rare Element holds a 100% interest in the Bear Lodge rare earth elements project (the “Bear Lodge REE Project”) located near the town of Sundance in northeast Wyoming. The Bear Lodge REE Project consists of several large, disseminated rare earth elements (“REE”) deposits that comprise one of the highest-grade REE deposits identified in North America. In addition, to neodymium-praseodymium (“Nd/Pr”), the Bear Lodge REE Project has a favorable distribution of a number of other critical rare earth elements. The Company also holds a 100% interest in the Sundance Gold Project that is adjacent to the Bear Lodge REE Project and contains a historical inferred mineral resource primarily composed of three gold targets within the area of the Bear Lodge property. Given the Company’s longstanding focus on the Bear Lodge REE Project and the current interest in REE, the advancement of the Sundance Gold Project has been on hold since 2011 and will likely remain so for the foreseeable future.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is currently focused on the advancement of a rare earth processing and separation demonstration-scale plant (the “Demonstration Plant”) project. In January 2021, a consortium of companies, of which the Company is a part, received notice from the Department of Energy (“DoE”) that the consortium had been selected for negotiation of a potential financial award for the engineering, construction and operation of a rare earth separation and processing Demonstration Plant. The consortium of companies is led by General Atomics, an affiliate of Synchron, the Company’s majority shareholder, and includes certain of General Atomics’ affiliates, and LNV, an Ardurra Group, Inc. company, as engineering and construction subcontractor. A formal proposal was submitted by the consortium in response to a published Funding Opportunity Announcement in mid-2020 for the construction and operation of a rare earth separation and processing demonstration plant utilizing proprietary technology to produce commercial-grade products. The DoE finalized the award, and an agreement was executed by the DoE’s grants/agreement officer on September 27, 2021, with an effective date of October 1, 2021. The Company, as a subrecipient of the award, along with the other consortium members, commenced work on the planning and design of the Demonstration Plant project in November 2021, with the Company’s contractual arrangement with General Atomics finalized in December 2021. The DoE funding is in the amount of $21,900 and represents approximately <span style="-sec-ix-hidden:Hidden_FVcwkIkjUUKwevwwDPThcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-half of the total estimated costs for the Demonstration Plant. The Demonstration Plant will process already stockpiled high-grade sample materials from the Bear Lodge REE Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To address the Company’s funding needs, during December 2021, the Company completed a rights offering for gross proceeds of approximately $25,400. The Company is using the net proceeds from the rights offering for the permitting, licensing, engineering, construction, and operation of the Demonstration Plant near the Company’s Bear Lodge REE Project. The previously noted $21,900 financial award from the DoE is expected to fund approximately <span style="-sec-ix-hidden:Hidden_-Sks8ARnVk2uq9mOHFqQww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-half of the expected total cost of the Demonstration Plant, with the balance of the required funding being provided by the Company utilizing the proceeds from the rights offering and the previously announced $4,400 grant from the Wyoming Energy Authority (“WEA”). To the extent that inflationary pressures would cause the Demonstration Plant’s total cost to exceed its initial estimate of $43,800, the Company and the DOE’s responsibility for funding any amounts in excess of the $43,800 would have to be further considered and determined.    </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During 2022 and through the first quarter of 2023, the Company continued its work on the Demonstration Plant project. This work is expected to continue over the remainder of 2023 and through the Demonstration Plant project’s expected completion date in the early part of 2025. In December 2022, the Demonstration Plant achieved its final engineering design milestone marking the completion of the DOE’s first go/no-go decision point. The completion of this milestone was a gating event for the DOE’s continued funding of the Demonstration Plant as provided for in the 2021 award grant.  Future gating milestones include the DOE National Environmental Policy Act of 1969 (NEPA) review following the completion of the Nuclear Regulatory Commission licensing in the second half of 2023 and the completion of the Demonstration Plant’s construction in the second half of 2024. Operations to process and separate the REE from the stockpiled sample materials are expected to follow the completion of the Demonstration Plant’s construction for an additional <span style="-sec-ix-hidden:Hidden_uEwCVcCzZk6_HoQ8zHtulQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eight</span></span>-to-10-month period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Even with the completion of the 2021 rights offering and expected receipt of the WEA grant monies, the Company will not have sufficient funds to progress other activities, including with respect to any potential additional costs that the Company may be asked to fund on the Demonstration Plant due to inflationary cost increases, as well as any feasibility studies, permitting, licensing, development, and construction related to the Bear Lodge REE Project. Therefore, the achievement of these other activities will be dependent upon the receipt of additional funds through financings, off-take agreements, joint ventures, strategic transactions, grants, or sales of various assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company has incurred losses since its inception, and further losses are anticipated in the development of its business. As of March 31, 2023, the Company had cash and cash equivalents of </span><span style="font-weight:normal;">$13,992</span><span style="font-weight:normal;"> and our cash used in operations during the three months ended March 31, 2023 was </span><span style="font-weight:normal;">$1,543</span><span style="font-weight:normal;">, of which approximately </span><span style="font-weight:normal;">$1,000</span><span style="font-weight:normal;"> was used for the payment of costs associated with the Demonstration Plant project, while the remainder was used for the payment of the Company’s general and administrative expenses and other ongoing costs of sustaining its properties and mining claims. </span></p>
CY2021Q4 reemf Amount Of Potential Funding For Project
AmountOfPotentialFundingForProject
21900000
CY2021Q4 reemf Rights Offering Authorized Amount
RightsOfferingAuthorizedAmount
25400000
CY2021Q4 reemf Amount Of Potential Funding For Project
AmountOfPotentialFundingForProject
21900000
CY2021Q4 reemf Amount Of Initial Estimate For Demonstration Plant
AmountOfInitialEstimateForDemonstrationPlant
43800000
CY2021Q4 reemf Amount Of Initial Estimate For Demonstration Plant
AmountOfInitialEstimateForDemonstrationPlant
43800000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13992000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1543000
CY2023Q1 reemf Payments For Demonstration Plant Project Costs
PaymentsForDemonstrationPlantProjectCosts
1000000
CY2021Q4 reemf Amount Of Potential Funding For Project
AmountOfPotentialFundingForProject
21900000
CY2021Q4 reemf Total Allowable Costs For Planned Demonstration Funded On Cost Share Basis
TotalAllowableCostsForPlannedDemonstrationFundedOnCostShareBasis
43900000
CY2021Q4 reemf Percentage Of Expected Total Cost Of Demonstration Plant Funded By Grant
PercentageOfExpectedTotalCostOfDemonstrationPlantFundedByGrant
0.50
CY2021Q4 reemf Percentage Of Expected Total Cost Of Demonstration Plant Funded By Non Federal Entity
PercentageOfExpectedTotalCostOfDemonstrationPlantFundedByNonFederalEntity
0.50
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
93000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
124000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
93000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
310000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
40000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
270000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
22000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1020000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1830000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0154
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0171
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.23
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4160000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.26
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2180000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.18
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1020000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.38
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1830000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.40
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5180000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.08
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4010000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.28
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3826250
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.31
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1752500
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.92
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1353750
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.44
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2257500
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.56
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
110000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
110000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2023Q1 reemf Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm
P9Y8M12D
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
172000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
995000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
359000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1353750
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.35

Files In Submission

Name View Source Status
reemf-20230331_lab.xml Edgar Link unprocessable
reemf-20230331x10q_htm.xml Edgar Link completed
reemf-20230331_def.xml Edgar Link unprocessable
0001419806-23-000010-index-headers.html Edgar Link pending
0001419806-23-000010-index.html Edgar Link pending
0001419806-23-000010.txt Edgar Link pending
0001419806-23-000010-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
reemf-20230331.xsd Edgar Link pending
reemf-20230331x10q.htm Edgar Link pending
reemf-20230331x10q001.jpg Edgar Link pending
reemf-20230331xex10d1.htm Edgar Link pending
reemf-20230331xex10d1001.jpg Edgar Link pending
reemf-20230331xex10d1002.jpg Edgar Link pending
reemf-20230331xex31d1.htm Edgar Link pending
reemf-20230331xex31d2.htm Edgar Link pending
reemf-20230331xex32d1.htm Edgar Link pending
reemf-20230331xex32d2.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
reemf-20230331_cal.xml Edgar Link unprocessable
reemf-20230331_pre.xml Edgar Link unprocessable